Clinical Trials
739 trialsNCT02519348 2026-06-03
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
Phase 2 Active not recruiting
NCT03937830 2026-06-03
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06486454 2026-06-03
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
HistoSonics, Inc.
Recruiting
NCT07444905 2026-06-03
Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma
Tongji Hospital
Active not recruiting
NCT07623265 2026-06-03
IO-MARC
Universitaire Ziekenhuizen KU Leuven
Phase NA Recruiting
NCT07623369 2026-06-03
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
Huahui Health
Phase 1 Not yet recruiting
NCT02379377 2026-06-02
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03823144 2026-06-02
Intravital Microscopy in Human Solid Tumors
Mayo Clinic
Phase NA Recruiting
NCT04954339 2026-06-02
DYNAMIC
Asan Medical Center
Phase 2 Completed
NCT07197554 2026-06-02
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
Phase 1 Recruiting
NCT07291076 2026-06-02
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07620574 2026-06-02
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis
Phase 3 Not yet recruiting
NCT03257761 2026-06-01
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
Phase 1 Active not recruiting
NCT05063565 2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT05507632 2026-06-01
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Active not recruiting
NCT05791448 2026-06-01
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
University of Southern California
Phase 1 Recruiting
NCT06096779 2026-06-01
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT06600321 2026-06-01
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Phase 1 Recruiting
NCT06995898 2026-06-01
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Phase NA Recruiting
NCT07617038 2026-06-01
HERO
Université de Montréal
Phase NA Enrolling by invitation
NCT07618546 2026-06-01
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
Henan Cancer Hospital
Phase NA Not yet recruiting
NCT02968810 2026-05-29
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03186898 2026-05-29
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT04175912 2026-05-29
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07419841 2026-05-29
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Phase 1 Recruiting
NCT04514484 2026-05-28
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05919264 2026-05-28
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT07483359 2026-05-28
CONV3RSION
First Hospital of China Medical University
Phase 2 Recruiting
NCT02867592 2026-05-27
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05176483 2026-05-27
STELLAR-002
Exelixis
Phase 1 Recruiting
NCT06544083 2026-05-27
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
NCT07495579 2026-05-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT07608458 2026-05-27
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
City of Hope Medical Center
Phase NA Not yet recruiting
NCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04982653 2026-05-26
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05620771 2026-05-26
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Recruiting
NCT07284121 2026-05-26
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Hoffmann-La Roche
Recruiting
NCT07607769 2026-05-26
MONTEROSA
AstraZeneca
Recruiting
NCT03520660 2026-05-22
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
National Institutes of Health Clinical Center (CC)
Phase 4 Active not recruiting
NCT03896646 2026-05-22
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT04687969 2026-05-22
Multimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
Completed
NCT04792801 2026-05-22
TEP CARE
University Hospital, Lille
Active not recruiting
NCT05053555 2026-05-22
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT05099848 2026-05-22
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Completed
NCT06066138 2026-05-22
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06084884 2026-05-22
ATHENA
AstraZeneca
Phase 1/2 Active not recruiting
NCT06187961 2026-05-22
CCGLC-011
Tongji Hospital
Phase 2 Active not recruiting
NCT06953089 2026-05-22
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 2 Recruiting
NCT07377487 2026-05-22
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT07405086 2026-05-22
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 4 Recruiting